Want to see DE:SRT3 full AI Analyst Report?
Top Page
Sartorius
(XETRA:SRT3)
Select Model
Select Model
Rating:57Neutral
Price Target:
€292.00
▲(18.46% Upside)
Action:Reiterated
Date:10/24/26
The score is held back primarily by leveraged financials, lower and more volatile net profitability, and uneven cash conversion despite strong revenue re-acceleration. Technicals are a clear positive with a strong uptrend and supportive momentum, but valuation is a major constraint given the very high P/E and minimal dividend yield.
Positive Factors
Revenue Re-acceleration
The sharp TTM revenue rebound indicates renewed demand across Sartorius’s life-science and bioprocessing activities. If sustained, stronger volume and customer investment can improve operating leverage, support reinvestment, and reinforce the company’s position in biologics-related workflows.
Negative Factors
Elevated Leverage
Elevated leverage remains a material constraint on financial flexibility even after improving from the 2023 peak. Debt obligations can limit room for acquisitions, investment, or resilience during weaker demand, while also increasing the consequences of any renewed profitability pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Re-acceleration
The sharp TTM revenue rebound indicates renewed demand across Sartorius’s life-science and bioprocessing activities. If sustained, stronger volume and customer investment can improve operating leverage, support reinvestment, and reinforce the company’s position in biologics-related workflows.
Read all positive factors
Sartorius (SRT3) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€17.41B
Dividend Yield0.26%
Average Volume (3M)115.58K
Price to Earnings (P/E)99.6
Beta (1Y)1.32
Revenue Growth4.19%
EPS Growth63.32%
CountryDE
Employees14,279
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.83
Shares Outstanding37,440,000
10 Day Avg. Volume134,301
30 Day Avg. Volume115,580
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€281.89Price Target Upside14.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)5.3
Revenue Forecast (FY)€3.73B
Sartorius Business Overview & Revenue Model
Company Description
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include...
How the Company Makes Money
Sartorius makes money primarily by selling products and services that enable customers to develop, scale, and manufacture biologic medicines and to run laboratory workflows. A major revenue stream is Bioprocess Solutions, where Sartorius supplies ...
Sartorius Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
44
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.58B | 3.54B | 3.38B | 3.40B | 4.17B | 3.45B |
| Gross Profit | 1.64B | 1.64B | 1.52B | 1.57B | 2.20B | 1.84B |
| EBITDA | 1.04B | 1.07B | 786.80M | 873.20M | 1.50B | 945.12M |
| Net Income | 171.40M | 154.90M | 84.00M | 205.20M | 913.10M | 426.98M |
Balance Sheet | ||||||
| Total Assets | 9.60B | 9.72B | 10.10B | 9.76B | 6.98B | 5.70B |
| Cash, Cash Equivalents and Short-Term Investments | 306.90M | 551.80M | 828.70M | 394.20M | 196.80M | 360.99M |
| Total Debt | 4.05B | 4.28B | 4.56B | 5.31B | 2.54B | 2.08B |
| Total Liabilities | 5.60B | 5.85B | 6.21B | 7.00B | 4.32B | 3.98B |
| Stockholders Equity | 2.82B | 2.71B | 2.76B | 2.07B | 1.99B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 292.90M | 214.10M | 566.30M | 293.90M | 211.60M | 458.65M |
| Operating Cash Flow | 734.40M | 656.00M | 976.20M | 853.60M | 734.20M | 865.81M |
| Investing Cash Flow | -504.70M | -513.50M | -425.80M | -2.82B | -1.13B | -569.61M |
| Financing Cash Flow | -760.50M | -410.60M | -128.30M | 2.17B | 209.90M | -165.18M |
Sartorius Technical Analysis
Positive
246.50
Price Trends
249.88
Positive
239.71
Positive
234.03
Positive
Market Momentum
6.13
Negative
69.77
Neutral
73.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT3, the sentiment is Positive. The current price of 246.5 is below the 20-day moving average (MA) of 259.16, below the 50-day MA of 249.88, and above the 200-day MA of 234.03, indicating a bullish trend. The MACD of 6.13 indicates Negative momentum. The RSI at 69.77 is Neutral, neither overbought nor oversold. The STOCH value of 73.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SRT3.
Sartorius Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €11.08B | 25.77 | 17.54% | 1.90% | 3.92% | 10.56% | |
74 Outperform | €3.18B | 21.28 | 5.52% | 1.55% | -0.06% | -38.81% | |
60 Neutral | €285.66M | -587.50 | -0.17% | 2.55% | ― | ― | |
59 Neutral | €1.61B | 23.69 | 12.29% | 4.49% | 0.35% | 116.73% | |
57 Neutral | €17.41B | 99.58 | 6.28% | 0.26% | 4.19% | 63.32% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €1.08B | -2.70 | -32.84% | 0.13% | 8.90% | -609.05% |
* General Sector Average
DE:SRT3
Sartorius
281.80
43.82
18.41%
DE:AFX
Carl Zeiss Meditec
35.54
-8.69
-19.64%
DE:G1A
GEA Group AG
68.55
6.45
10.38%
DE:GXI
Gerresheimer
31.34
1.94
6.60%
DE:PFV
Pfeiffer Vacuum Technology
163.00
14.07
9.45%
DE:SBS
STRATEC Biomedical
23.50
-1.39
-5.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.